ACE-2-like Enzymatic Activity in COVID-19 Convalescent Patients with Persistent Pulmonary Symptoms Associated with Immunoglobulin

Yufeng Song[1], Frances Mehl[1], Lyndsey M. Muehling[2], Glenda Canderan[2], Kyle Enfield[2], Jie Sun[3,4], Michael T. Yin[5], Sarah J. Ratcliffe[6], Jeffrey M. Wilson[7], Alexandra Kadl[2,8], Judith Woodfolk[7,8], Steven L. Zeichner[1,9]*

[1]Department of Pediatrics, University of Virginia, Charlottesville, VA

[2]Department of Medicine, University of Virginia, Charlottesville, VA

[3]Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA

[4]Division of Infectious Disease and International Health, Department of Medicine, University of Virginia, Charlottesville, VA

[5]Columbia University Vagelos College of Physicians and Surgeons, New York, NY

[6]Division of Biostatistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA

[7]Division of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, VA

[8]Department of Pharmacology, University of Virginia, Charlottesville, VA

[9]Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA

*Correspondence: zeichner@virginia.edu

Abstract

Many difficult to understand clinical features characterize COVID-19 and Post-Acute Sequelae of COVID-19 (PASC or Long COVID, LC). These can include blood pressure instability, hyperinflammation, coagulopathies, and neuropsychiatric complaints. The pathogenesis of these features remains unclear. The SARS-CoV-2 Spike protein Receptor Binding Domain (RBD) binds Angiotensin Converting Enzyme 2 (ACE2) on the surface of host cells to initiate infection. We hypothesized that some patients may produce anti-RBD antibodies that resemble ACE2 sufficiently to have ACE2-like catalytic activity, that is they are ACE2-like proteolytic abzymes that may help mediate the pathogenesis of COVID-19 and LC. In previous work, we showed that some acute COVID-19 patients had immunoglobulin-associated ACE2-like proteolytic activity, suggesting that some COVID-19 patients indeed produced ACE2-like abzymes. However, it remained unknown whether ACE2-like abzymes were seen only in acute COVID-19 patients or whether ACE2-like abzymes could also be identified in convalescent COVID-19 patients. Here we show that some convalescent COVID-19 patients attending a clinic for patients with persistent pulmonary symptoms also have ACE2-like abzymes and that the presence of ACE2-like catalytic activity correlates with alterations in blood pressure in an exercise test.

45 ## Introduction

46 The COVID-19 pandemic has had a devastating effect on world health. An estimated 7M
47 have died so far [1], even with the availability of effective vaccines and antivirals. Beyond COVID-
48 19's acute effect, its long-term effects have had grave effects on individual patients and society.
49 Among the most challenging secondary consequences of COVID-19 are patients affected by
50 Post-Acute Sequelae of COVID-19 (PASC, or Long COVID, LC), reviewed in [2-4], which may
51 affect as many as 7% of COVID-19 patients [5]. Many studies have described the epidemiology
52 and clinical manifestations of LC, and associated LC with various clinical findings, but no clear
53 fundamental, causal mechanisms have been established [6]. LC symptoms can include post-
54 exertional malaise, fatigue, "brain fog" and other neuropsychiatric symptoms, dizziness, GI
55 complaints, cardiovascular complaints like palpitations, libido changes, alterations in smell or
56 taste, cough, chest pain, and abnormal movements [7]. Many LC patients exhibit abnormal clinical
57 features, including blood pressure dysregulation, coagulopathies, and inflammation. [8, 9]. Patients
58 with LC have been found to have distinct immune profiles compared to matched subjects
59 without LC, including altered populations of lymphoid and myeloid cells, altered levels of
60 immune mediators and hormones and increased humoral immune responses against SARS-
61 CoV-2 [10]. Proteomic studies have shown that LC patients have evidence of persistent activation
62 of the complement (C') system with increased concentrations of complement proteolysis
63 products and proteolysis by thrombin [11], but these findings have not identified a proximate
64 cause underlying the disease. Since no proximate cause of LC has been identified, no specific
65 therapies are available, and these patients continue to suffer and are treated only with non-
66 specific therapies directed at one or another symptom.

67 We noted that proteolytic regulatory cascades control many of the physiologic pathways
68 dysregulated in COVID-19 and LC, such as blood pressure regulation (angiotensin), coagulation
69 (thrombin), and inflammation (C', kallikrein-kinin) [12-14]. Some of the problematic clinical disorders
70 related to COVID-19 do not become apparent until a week or more after infection, so their
71 underlying pathogenesis is likely due to secondary or reactive processes and not due to primary

72 cytotoxicity from acute viral replication. Additional data suggests that some of the COVID-19-
73 associated inflammatory processes may involve antibodies against SARS-CoV-2 spike protein,
74 S. For example, a small number of patients who received SARS-CoV-2 vaccines and had no
75 evidence of SARS-CoV-2 infection exhibit disordered inflammatory responses, blood pressure
76 dysregulation or coagulopathy[15]., and a small number of infants born to mothers with COVID-19
77 have been described as having multi-system inflammatory syndrome of children (MIS-C) [16]
78 Since many of COVID-19 and LC's puzzling features appear to involve physiologic
79 regulatory cascades controlled by proteolysis, we considered how infection with SARS-CoV-2
80 might yield pathologies involving proteolytic regulatory cascades. We noted that angiotensin
81 converting enzyme 2 (ACE2) is SARS-CoV-2's host cell receptor [17]. ACE2 exists both free in the
82 circulation and in the membranes of cells of several tissues. While angiotensin converting
83 enzyme (ACE) cleaves angiotensin I to yield angiotensin II, a vasoconstrictor that increases
84 blood pressure [18], ACE2 acts in a counter-regulatory fashion to ACE, cleaving angiotensin II to
85 yield angiotensin 1-7, a vasodilator that lowers blood pressure [19]. We recalled the literature
86 concerning catalytic antibodies or "abzymes" [20, 21]. When abzymes were first identified,
87 researchers created abzymes by making anti-idiotypic antibodies against antibodies that
88 themselves had been produced against the active site of a particular enzyme of interest[22, 23].
89 Some of the anti-idiotypic antibodies resembled the enzyme's active site sufficiently for the
90 antibody to have catalytic activity like that of the original enzyme[24, 25]. However, some abzymes
91 exhibited substrate specificities that differed notably from those of the original enzyme's [23, 24, 26].
92 The abzymes exhibited substrate promiscuity compared to the original enzyme and had
93 catalytic activity that was lower than the activity typically seen with more conventional
94 enzymes (*k*cat/*Km* values ~10^2 - 10^4 s^{-1}•M s^{-1} [27] vs. *k*cat/*Km* values of ~10^5 s^{-1}•M s^{-1})[28].
95 The poorer activity, in addition to the problems with substrate specificity spread, led to
96 decreased interest in abzymes as a new biotechnology.
97 We hypothesized that some COVID-19 patients may develop antibodies with catalytic
98 activity because the RBD, since it binds ACE2, should have a partial negative image of ACE2,

99 so some anti-RBD antibodies may have enough similarity to ACE2 to have proteolytic activity
100 similar to ACE2, or perhaps other proteolytic enzymes due to substrate specificity spread seen
101 with abzymes. ACE2 can cleave many peptides with important physiologic activity beyond
102 angiotensin II [29]

103 There are examples of patients who produce abzymes with potentially clinically
104 significant effects, for example DNA [30], immunoglobulin [31], vasoactive intestinal peptide
105 (VIP)[32], myelin basic protein (MBP) in multiple sclerosis patients [33], and factors in the
106 coagulation cascade [34-36]. Some patients with HIV have been shown to produce
107 abzymes that cleave HIV Env, so there exist examples of cases where viral infection
108 induces production of an abzyme [37].

109 In previous work [38], we showed that some patients with acute COVID-19
110 produced antibodies with ACE2-like catalytic activity. However, the question remained
111 whether antibodies with ACE2-like catalytic activity were present in convalescent
112 COVID-19 patients and, if so, whether the presence of ACE2-like catalytic activity
113 correlated with any plausible clinical findings. Here we show results obtained from 20
114 convalescent COVID-19 patients who attended a clinic at the University of Virginia for
115 convalescent COVID-19 patients with persistent pulmonary symptoms. Prior work
116 identified persistent inflammation and immune dysregulation within these individuals,
117 including auto-reactive antibodies [39]. We found that six of those patients had ACE2-like
118 antibody-associated catalytic activity in their plasma, and that the presence of ACE2-like
119 antibody-associated catalytic activity correlated with lower blood pressure after a six-
120 minute walk test, indicating that ACE2-like abzyme activity occurs in both acute and
121 convalescent COVID-19 patients and can have associations with physiologic
122 consequences.

123 # Methods

124 ## Clinical Cohort

125 We studied a subset of individuals from a previously published cohort of COVID-19
126 convalescent patients at the University of Virginia [39] of COVID-19 convalescent patients
127 who attended a post-COVID pulmonary clinic for follow-up care (COVID Recovery
128 Cohort (COVID-RC)). All patients had confirmed prior COVID-19 infection. Twenty
129 patients, spanning a broad range of anti-Spike IgG levels (2.1-314.6 μg/mL), with
130 available plasma biospecimen, were selected for abzyme studies. The characteristics of
131 the patients selected for abzyme studies are listed in Table 1. Most patients were
132 hospitalized during acute infection (70%), with 30% requiring mechanical ventilation.
133 Patients initially contracted COVID-19 from March 2020-March 2022, with the majority
134 becoming infected prior to the circulation of major viral variants (70%). SARS-CoV-2
135 anti-spike and anti-capsid IgG was measured by ImmunoCAP assay[38, 40]. Approximately
136 half of the selected subjects (55%) had received at least one SARS-CoV-2 vaccine
137 dose at the time of sample collection. While there was a statistically significant
138 association between receipt of at least one dose of vaccine and anti-spike IgG, there
139 was no significant association between vaccine receipt and the presence of ACE-2-like
140 catalytic antibodies and no statistically significant association between anti-spike IgG
141 level and the presence of ACE-2-like catalytic antibodies.

142

143 ## Clinical and Other Data

144 Clinical data collected from the patients in the cohort included a symptom inventory. A
145 six-minute walk test was given to 18 of the patients included in this study, in which heart
146 rate, systolic and diastolic blood pressures were recorded before and after the test walk.
147 Data on plasma cytokines TNF-α and IL-6 was obtained for 12 patients, as previously

148 described[39].To explore whether inflammatory cytokine markers might correlate with the
149 presence of ACE2-like catalytic activity, we examined TNF-α and IL-6 levels for some of
150 the patients, but found no statistically significant correlations. Table 2 summarizes this
151 data.
152
153 **Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection**
154 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II
155 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)
156 providing a synthetic ACE2 peptide substrate labeled with a fluor and a quencher with a
157 lower limit of detection for an unmodified assay of 400 μU as described [38]. Recombinant
158 human ACE2 (ACE2) as a positive control is also included in the assay kit. ACE2
159 inhibitor provided in the assay kit was also used for additional controls. Briefly, 50μl
160 plasma or diluted plasma (in PBS without Ca^{2+} or Mg^{2+}, and with 4mM EDTA added)
161 was added to wells in a 96-well black flat bottom assay plate (Corning, Cat. #3603) and
162 incubated at room temperature (RT), in the dark for 15 min. Then, 50μl pre-diluted
163 substrate was added into the wells of the plate, mixing the substrate with the plasma
164 sample. The plate was immediately placed into a SpectraMax® M5 multi-model
165 microplate reader (Molecular Devices). After 3 minutes incubation, the Relative
166 Fluorescent Unit (RFU, Ex/Em = 320/420 nm) values were measured in kinetic mode
167 every 20 min for a total of 16 hours at 37℃. We performed assays on normal human
168 plasma spiked with serial dilutions of rACE2 to determine the lower limits of detection
169 for the assay (Figure S1). We then defined as ~~a~~ “positive” samples that had RFU slopes
170 (between 5 and 120 minutes) that were greater than or equal to 2-fold the slope of the
171 lower limit of detection of serial dilution assays using rACE2 spiked into normal human
172 plasma.

173 We conducted negative control experiments using the ACE2 inhibitor from the
174 assay kit for additional controls.
175
176 **Human Immunoglobulin Depletion and Detection**
177 We depleted immunoglobulin from the plasma samples as previously described in detail
178 [38]. Plasma samples were 1:8 diluted in PBS with 4 mM EDTA and centrifuged at 12,000
179 × g at 4 ℃ for 15 min followed by passing through 0.45 μm syringe filter
180 (FisherScientific, Cat. #97204). We loaded 500 μL of the filtered samples onto
181 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #
182 88503) and centrifuged the columns at 12,000 × g at 4 ℃ until > 400 μL of filtrate was
183 produced. The flow-through fractions were then incubated with 30 μL pre-washed
184 Protein A/G Magnetic Beads (Life Technologies, Cat. # 88803, 10 mg/mL) at room
185 temperature (RT) for 1 hour, and repeated a second time to further deplete the
186 antibodies. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.
187 #ab100547) according to the manufacturer's protocol as described [38]. Briefly, 100 μl
188 samples, as well as standards, were added into each well of multi-microwell strips and
189 incubated at room temperature for 2.5 hours. Biotin-labeled IgG detection antibody was
190 then added to each well after wash and incubated at room temperature for 1 hour.
191 Then, HRP-streptavidin was added at room temperature for 1 hour. After wash, OD
192 values were developed by adding TMB One-Step Substrate and Stop Solution
193 subsequently. OD values were read at 450 nm using an accuSkan FC micro-well plate
194 reader (ThermoFisher). IgG concentrations were calculated based on standard curves
195 generated with the same batch of assay strips. Our depletion protocol removes
196 >99.99% of human IgG and IgM from the plasma samples[38].
197

198 **ACE2 Substrate Peptide Cleavage Competition Inhibition by SARS-CoV-2 Spike**
199 **RBD Peptide Pools**

200 As described previously [38] we synthesized tiled SARS-CoV-2 spike protein RBD
201 (receptor binding domain) peptides (SB-PEPTIDE, SmartBioscience SAS, France) from
202 residues Arg319 to Phe541, including receptor binding motif (RBM) from Ser438 to
203 Gln506, based on a published analysis on viral-host interaction [41]. We added 10μg per
204 peptide to selected plasma samples, diluted 1:8 dilution with PBS with 4 mM EDTA.
205 Recombinant human ACE2 protein, supplied in the kit served as a positive control.
206 Sample-peptide pool mixtures were incubated at RT for 15 min in dark before adding
207 the substrate. Samples incubated with ddH_2O and DMSO (1:1 mixture), equivalent to
208 the concentrations of the peptide pool reconstitution served as negative controls.
209 Relative Fluorescent Units were measured as described above, and data was analyzed
210 as described below.
211

212 **Data Analysis**

213 As previously described [38], RFU values observed over 120 min were used to evaluate
214 ACE2 substrate cleavage activities in those plasma samples. Corrected value of each
215 sample was calculated by subtracting baseline RFU value from the value at each
216 subsequent time point and the sum of baseline-corrected value over 120 min was also
217 calculated using R. The change in RFU over the first 120 minutes of the assay was
218 calculated using linear regression and was used as a measure of ACE2-like activity.
219 Correlations between ACE2 like activity and clinical data were assessed using
220 Pearson's product-moment correlation for numerical variables and Kruskal-Wallis
221 rank/sum test for categorical variables. Data analysis and visualization was performed

with R (version 2022-06-23) using the Rstudio user interface with packages including ggplot2, tidyverse, readr, drc, ggpubr, ggh4x, stringr, and patchwork.

226 **Results**

227 To determine whether COVID-19 convalescent patients produced antibodies with
228 ACE2-like catalytic activity, similar to those we identified in acute COVID-19 patients [38],
229 we studied samples available from 20 patients from an existing cohort available at the
230 University of Virginia for which plasma samples and clinical testing was available. This
231 cohort, already described[39], enrolled convalescent COVID-19 patients, the majority of
232 whom reported persistent pulmonary symptoms. The demographic characteristics of the
233 cohort are described in Table 1.

234 We conducted ACE2 activity assays on 20 plasma samples from these patients.
235 We found that 6 of them had ACE2-like catalytic activity greater than or equal to 2-fold
236 above the lower limits of detection for ACE2 as determined by serial dilution
237 experiments using rACE2, our conservative criteria for positive ACE2-like activity. An
238 additional 5 patients had borderline positive ACE2-like activity, with levels greater than
239 or equal to the lower limits of detection of the rACE2, but less than the 2-fold greater
240 than the lower limit of detection cut-off (FIGs 1 and 2).

241 To determine whether the ACE2-like activity was associated with immunoglobulin
242 in these samples, we conducted an immunoglobulin depletion procedure, that included
243 depleting molecules >100 KDa using a centrifugal ultrafiltration column followed by a
244 protein A/G absorption step. The procedure yielded samples that were depleted in
245 immunoglobulin by >99.9% (Table 3).

246 We conducted the ACE2-like activity assays on the immunoglobulin-depleted
247 plasma samples from the patients who were found to be positive for ACE2-like activity.
248 The immunoglobulin-depleted samples had no ACE2-like activity, supporting the
249 hypothesis that the ACE2-like activity is antibody-associated (FIG 3).

250 To further confirm the specificity of the ACE2-like activity, we conducted assays
251 on the samples in the presence of tiled overlapping peptides that included the RBD site
252 in the spike protein [38]. Competition with using the overlapping spike RBD region
253 peptides strongly inhibited the ACE2-like cleavage activity present in the patient plasma
254 samples, further confirming that the ACE2-like activity was specific for an RBD-
255 interacting activity of the plasma antibodies. There was a modest decrease when the
256 competing peptide diluent was added alone, probably because addition of the diluent
257 increased the volume of the material assayed in the wells (FIG 4).
258 The cohort studied here consisted of patients with persistent pulmonary
259 symptoms (complaints of cough, difficulty breathing, or dyspnea on exertion) not
260 patients enrolled specifically because they had symptoms that could be considered
261 characteristic for LC. Nevertheless, several patients in this cohort had a variety of
262 symptoms beyond the strictly pulmonary symptoms. Table 2 lists the range of
263 symptoms reported in this cohort.
264 If SARS-CoV-2 infection elicits the production of abzymes, it would be important
265 to know if those abzymes were associated with any clinical features. Here, we focused
266 on catalytic antibodies with ACE2-like activity, so for this study our interests centered on
267 whether there would be a correlation in the patients between ACE2-like catalytic activity
268 and a physiologic variable that could be related to dysregulated ACE2-like activity.
269 ACE2 catalyzes the cleavage of the vasoconstrictor angiotensin II to the
270 counterregulatory vasodilator angiotensin 1-7. A dysregulation of angiotensin 1-7
271 production might be expected to prevent a patient from maintaining ideal vascular tone.
272 So, if a patient has an ACE2-like catalytic antibody in the circulation, we hypothesized
273 that they may experience problems with blood pressure regulation, particularly after an
274 event that demanded a physiologic response to maintain blood pressure homeostasis,

like an exercise challenge. Thus, we asked whether patients with higher ACE2-like abzyme activities were less likely to maintain their blood pressures during a 6-minute walk test. Analysis of data from 18 patients revealed a significant correlation between the change in systolic blood pressure after 6 minute walk test and ACE2-like activity, with patients showing higher ACE2-like activity experiencing greater decreases in systolic blood pressure ($r=-0.54$, $p=0.021$). Non-statistically significant trends associated ACE-2 like catalytic activity with an increase in heart rate after the six-minute walk test and the absolute systolic blood pressure after six-minute walk test (FIG 5).

284 ## Discussion

285 Our prior work [38] showed that some patients with acute COVID-19 produced
286 antibodies that had ACE2 catalytic activity (ACE2-like abzymes) and that abzyme
287 activity correlated with RBD binding activity. However, that study involved only patients
288 with acute COVID-19, and did not address whether the ACE2-like abzyme activity
289 persisted after resolution of the acute disease into the convalescent period. In this
290 study, we show that some patients convalescing from COVID-19 also have antibodies
291 with ACE2-like abzyme activity, and that the presence of ACE2-like abzyme activity
292 correlates with a physiologically plausible clinical finding, namely decrease in blood
293 pressure after six-minutes of walking.

294 The finding that patients convalescing from COVID-19 can have circulating
295 ACE2-like abzymes that correlate with a clinical finding supports the hypothesis that
296 post-COVID-19 circulating abzymes could be involved in other aspects of disorders
297 observed in patients convalescing from COVID-19. These could conceivably include
298 some of the clinical features of LC, since many of the clinical problems observed in LC
299 patients include features that can be mediated by proteolytic regulatory cascades,
300 although considerable additional work on larger cohorts with different clinical
301 manifestations of LC, and additional assays for other antibody-associated catalytic
302 activity would be needed to establish such associations. However, the hypothesis is
303 highly testable, able to inform clear, follow-on studies, such as studies to determine if
304 convalescent COVID-19 patients with LC have circulating abzymes that can affect
305 additional proteolytic regulatory cascades capable of mediating one or another aspect of
306 LC pathogenesis. If pathophysiologically active SARS-CoV-2-induced abzymes are
307 found, they could offer a plausible target for the development of new therapies, which

308 could be useful, since there are no currently available therapies directed at a proximate
309 cause of LC.
310 Our study had several strengths. We studied a well-defined cohort of patients,
311 who had clear, persistent pulmonary symptoms after convalescing from acute COVID-
312 19. Additional objective clinical and laboratory information was available for these
313 patients, enabling us to conduct preliminary analyses to determine whether there any
314 clinical features that correlated with the presence of ACE2-like abzymes. We used a
315 well-characterized ACE2 peptide substrate cleavage activity kit, and available size
316 exclusion columns, protein A/G bead absorption immunoglobulin depletion procedures,
317 and standard, available immunoglobulin assays.
318 Our study also has several limitations. We studied moderate number of patients
319 with a single subset of post-COVID-19 clinical complaints, restrictive lung disease [39]. A
320 much larger study or series of studies, involving many more patients with a variety of
321 distinct principal manifestations of post-acute COVID-19 symptoms, ideally clearly
322 defined LC symptomatology and additional, multiple comprehensive assays for
323 antibody-associated catalytic activity would be needed to firmly support the abzyme
324 hypothesis, but such work would be outside the scope of this study and samples that
325 were available to us at the time of the study. The limitation of the cohort to those
326 patients with lung disease may also have limited any relationships between the
327 presence of ACE2-like abzyme activity and physiological variables, particularly
328 cardiovascular variables, since those are influenced by pulmonary disease. The
329 persistent pulmonary symptoms that define this cohort likely result from many causes,
330 perhaps most likely direct damage to lung parenchyma by viral replication and the
331 secondary host inflammatory response. The cohort was not limited to patients who met
332 a strict LC definition, so while some patients had symptoms that could be characterized

333 as belonging to the spectrum of LC, other patients in the cohort did not have such
334 symptoms. Additional studies of a cohort specifically comprised of LC patients would be
335 needed to determine whether LC symptoms were specifically associated with abzymes
336 that had one or another catalytic activities. Other factors could certainly mediate the
337 clinical symptoms that trouble LC patients. It is likely that LC symptoms have more than
338 one cause. Among those other causes could be SARS-CoV-2 elicited abzymes with
339 catalytic activities other than ACE2-like catalytic activities, but we were not able to test
340 for those other activities in this study due to sample quantity constraints.
341 Finally, to definitively establish that an antibody induced by SARS-COV-2 has
342 catalytic activity with potentially clinically meaningful effects, it would be necessary to
343 isolate and study the antibody in pure form, something also outside the scope of this
344 study.
345 Nonetheless, our study shows that some COVID-19 convalescent patients make
346 antibodies with catalytic activity, a useful next step in understanding the pathogenesis of
347 COVID-19 and LC.
348
349 **Institutional Review Board Statement:** The University of Virginia Institutional Review
350 Board approved enrollment of all subjects and collection of specimens and related
351 metadata (HSR #HSR13166).
352
353 **Informed Consent Statement:** Informed consent was obtained from the subjects in the
354 study.
355
356 **Data Availability Statement:** Data is presented in the manuscript. Raw data is
357 available upon request.

Acknowledgments and Funding: The study was supported by internal funding from the University of Virginia, including the Manning Fund for COVID-19 Research at UVA the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease Research, and grants from NIAID, NIH (R01 AI176515, R21 AI138077, R56 AI178669). We thank the patient volunteers for generously agreeing to be research subjects in the study, and Deborah Murphy RN who assisted with enrollment of study participants).

Conflicts of Interest: The authors declare no conflict of interest.

Tables

371 **Table1**
372
373 Demographic and clinical characteristics of the patients included in the study.
374

Patient Characteristics (n=20)	
Age(yrs)	54+/-19
Sex	Male (55%), Female (45%)
Race	White (85%), Black (10%), Other (5%)
Days since start of illness	201 +/-129
Hospitalized for Covid	Yes (70%), No (30%)

375
376

Table 2.

Symptoms, cytokine assays, and physiologic measurements conducted on the patients in the study.

For the data listed under the six-Minute Walk Test heading, Pre-HR is the heartrate before the walk, Post-HR is the heartrate after the walk, Change HR is (PostHR – PreHR), Pre SBP is the systolic blood pressure before the walk, Post SBP is the systolic blood pressure after the walk, Change SBP is (Pre SBP – Post SBP), Pre DBP is the diastolic blood pressure before the walk, Post DBP is the diastolic blood pressure after the walk, Change DBP is (Pre DBP – Post DBP).

Symptoms	
Pulmonary Symptoms	*Patients with Symptom*
Cough	40%
Breathing Difficulty	10%
Dyspnea on exertion	80%
Other Symptoms	
Headache	10%
Weakness	15%
Fatigue	60%
Dizzy/Lightheaded/Syncope	20%
Brain fog/Memory Problems	35%
Sleep Disruption	45%
Pain	25%
Numbness	15%
Inflammatory Cytokines (n=12)	
TNF-α (pg/mL)	58 +/-52
IL-6 (pg/mL)	3.2 +/-3.2
Six-Minute Walk Test (n=18)	
Pre-HR (beats/minute)	88 +/-12
Post-HR (beats/minute)	111 +/-19
Change HR (beats/minute)	23 +/-13
Pre SBP (mmHg)	137 +/-17
Post SBP (mmHg)	145 +/-23
Change SBP (mmHg)	8 +/-16
Pre DBP (mmHg)	80 +/-8
Post DBP (mmHg)	82 +/-12
Change DBP (mmHg)	2 +/-9

391 **Table 3**
392
393 ***Immunoglobulin depletion following high molecular weight depletion and protein***
394 ***A/G bead absorption.***
395 Assays for the IgG concentration were conducted in triplicate.
396
397

Patient	Plasma IgG Concentration Mean +/-SD		IgG Depletion Efficiency
	Pre-IgG Depletion (mg/ml)	Post-IgG Depletion (ng/ml)	
#1	1.62 +/-0.01	0.19 +/-<0.001	>99.99%
#3	0.40 +/-0.01	0.19 +/-<0.001	>99.99%
#5	1.82 +/-0.02	0.19 +/-<0.001	>99.99%
#9	0.82 +/-0.05	0.19 +/-<0.001	>99.99%
#11	0.53 +/-0.01	0.19 +/-<0.001	>99.99%
#16	0.45 +/-0.08	0.19 +/-0.003	>99.99%
#2	1.03 +/-0.01	0.19 +/-0.000	>99.99%
#20	0.63 +/-0.04	0.19 +/-0.001	>99.99%
#14	1.27 +/-0.02	0.18 +/-0.001	>99.99%
#13	0.60 +/-0.01	0.18 +/-0.001	>99.99%
HDP	2.86 +/-1.72	0.03 +/-0.004	>99.99%

398
399
400
401

402 **FIG 1. ACE-2-Like Activity in Convalescent Patient Plasma**
403
404 Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma
405 from 20 COVID-19 convalescent patients with persistent pulmonary symptoms,
406 conducted with a fluor-quench tagged peptide substrate, as described in [38]. We
407 determined the assay slopes over 5-120 minutes and then conservatively called as a
408 positive any sample with a 5-120 minute slope greater than twice the slope of the lower
409 limit of detection of the positive control (recombinant ACE2) (FIG S1).



410

FIG 2. Distribution of ACE-2-like activity in the Convalescent Patients

Distribution of the 5-120 minute ACE2-like enzymatic activity slopes from Fig 1, compared to the recombinant humant rACE2 positive control. We found that 6 out of the 20 plasma samples had slopes that we considered positive, with slopes greater than that observed for the rACE2 positive control at twice the lower limit of detection. An additional 5 patients had ACE2-like catalytic activity with 5-120 minute slopes (RFU/min) greater than or equal to the slope observed with rACE2 at the lower limit of detection.



FIG 3. ACE2-like Activity in Patient Samples Depleted of Immunoglobulin

Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma of the 6 out of 20 COVID-19 convalescent patients with persistent pulmonary symptoms positive for ACE2-like activity in FIGs 1 and 2, conducted with a fluor-quench tagged peptide substrate, with immunoglobulins depleted as described in the Methods and [38].



FIG 4. Inhibition of ACE2-like catalytic activity in plasma from COVID-19 convalescent patients by pooled tiled RBD peptides.

Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma from 20 COVID-19 convalescent patients with persistent pulmonary symptoms, conducted with a fluor-quench tagged peptide substrate, with ACE2 activity competed using tiled overlapping RBD peptides as described in [38].



FIG 5. Correlation between cardiovascular six-minute walk stress test variables and ACE2-like catalytic activity.

A. Change in systolic blood pressure vs. ACE2-like catalytic activity. B. Change in heart rate vs. ACE2-like catalytic activity. C. Systolic blood pressure vs. ACE2-like catalytic activity. The change in systolic BP had a correlation of -0.54, p = 0.021. The changes in heart rate (correlation -0.29, p = 0.241) and absolute systolic blood pressure after the 6 minute walk (correlation 0.34, p = 0.178) were not significant (Pearson's product moment correlation).



References

1. Organization WH. WHO COVID-19 dashboard. World Health Organization; 2024 [cited 2024 24 June]; https://data.who.int/dashboards/covid19/deaths.

2. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nature Reviews Immunology. 2023;23(10):618-34.

3. Perumal R, Shunmugam L, Naidoo K, Abdool Karim SS, Wilkins D, Garzino-Demo A, Brechot C, Parthasarathy S, Vahlne A, Nikolich JŽ. Long COVID: a review and proposed visualization of the complexity of long COVID. Frontiers in immunology. 2023;14:1117464.

4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-46.

5. Adjaye-Gbewonyo D, Vahratian A, Perrine CG, Bertolli J. Long COVID in Adults: United States, 2022. 26/2023.

6. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473-87. PMC9132392

7. Marchi M, Grenzi P, Serafini V, Capoccia F, Rossi F, Marrino P, Pingani L, Galeazzi GM, Ferrari S. Psychiatric symptoms in Long-COVID patients: a systematic review. Frontiers in Psychiatry. 2023;14:1138389.

8. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, Walker TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Horwitz LI, Foulkes AS, Authors RC, Consortium R. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934-46.

9. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102-e7. PMC8691845

10. Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott IM, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng TJ, Xu L, Geraghty AC, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick JD, Kaminski N, Omer SB, Krumholz HM, Guan L, Dela Cruz CS, van Dijk D, Ring AM, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature. 2023 Nov;623(7985):139-48. PMC10620090

11. Cervia-Hasler C, Brüningk SC, Hoch T, Fan B, Muzio G, Thompson RC, Ceglarek L, Meledin R, Westermann P, Emmenegger M, Taeschler P, Zurbuchen Y,

Pons M, Menges D, Ballouz T, Cervia-Hasler S, Adamo S, Merad M, Charney AW, Puhan M, Brodin P, Nilsson J, Aguzzi A, Raeber ME, Messner CB, Beckmann ND, Borgwardt K, Boyman O. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024 Jan 19;383(6680):eadg7942.

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. PMC7159299

13. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397

14. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. PMC7869028

15. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

16. De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 2022;14(4):750.

17. Oudit GY, Wang K, Viveiros A, Kellner MJ, Penninger JM. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic. Cell. 2023 Mar 2;186(5):906-22. PMC9892333

18. Khurana V, Goswami B. Angiotensin converting enzyme (ACE). Clin Chim Acta. 2022 Jan 1;524:113-22.

19. Turner AJ, Nalivaeva NN. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022 May;151:170766. PMC8830188

20. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec 19;234(4783):1566-70.

21. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody. Science. 1986 Dec 19;234(4783):1570-3.

22. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5.

23. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9.

24. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8876-80. PMC47463

25. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar 31;750:265-70.

26. Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec 18;46(50):14598-609.

27. Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem. 2000;69:751-93.

28. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 2011 May 31;50(21):4402-10.

29. Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 2018 May;14(5):325-36. PMC6192041

30. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.

31. Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.

32. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun 9;244(4909):1158-62.

33. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6. PMC1324791

34. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May 30;39(21):6459-65.

35. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun 1;180(11):7714-20.

36. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999 Sep;5(9):1044-7.

37. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB, Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan 10;45(1):324-30.

38. Song Y, Myers R, Mehl F, Murphy L, Brooks B, Wilson JM, Kadl A, Woodfolk J, Zeichner SL. ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients. mBio. 2024 Apr 10;15(4):e0054124. PMC11005375

39. Canderan G, Muehling LM, Kadl A, Ladd S, Bonham C, Cross CE, Lima SM, Yin X, Sturek JM, Wilson JM, Keshavarz B, Bryant N, Murphy DD, Cheon IS, McNamara CA, Sun J, Utz PJ, Dolatshahi S, Irish JM, Woodfolk JA. Distinct Type 1 Immune Networks Underlie the Severity of Restrictive Lung Disease after COVID-19. bioRxiv. 2024:2024.04.03.587929.

40. Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A, Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. Int Arch Allergy Immunol. 2021;182(5):417-24. PMC8018212

41. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 2020/05/01;581(7807):215-20.